Vasoactive and permeability effects of vascular endothelial growth factor-165 in the term in vitro dually perfused human placental lobule

被引:34
|
作者
Brownbill, P.
McKeeman, G. C.
Brockelsby, J. C.
Crocker, I. P.
Sibley, C. P.
机构
[1] Univ Manchester, Sch Med, Div Human Dev, Manchester M13 0JH, Lancs, England
[2] Queens Univ Belfast, Sch Med, Dept Obstet & Gynaecol, Belfast BT7 1NN, Antrim, North Ireland
[3] Cmabridge Univ Hosp, Addenbrookes Hosp, Natl Hlth Serv Fdn Trust, Cambridge DB2 2OO, England
关键词
D O I
10.1210/en.2007-0180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Vascular endothelial growth factor (VEGF) is an important vasodilator and effector of permeability in systemic blood vessels. Molecular and tissue culture techniques have provided evidence for its placental synthesis and release. Using an in vitro dual-perfusion model of the term placental lobule from normal pregnancy, we report here the relative secretion of total VEGF, soluble VEGF receptor (VEGFR)-1, and free VEGF into the maternal and fetoplacental circulations of the placenta. We tested the hypothesis that VEGF has vasomotor and permeability effects in the fetoplacental circulation of the human placenta, and we examined the broad intracellular pathways involved in the vasodilatory effect that we found. We show that total VEGF is released into the fetal and maternal circulations in a bipolar fashion, with a bias toward maternal side output. Soluble VEGFR-1 was also secreted into both circulations with bias toward the maternal side. Consequently, free VEGF (12.8 +/- 2.4 pg/ml, mean +/- SE) was found only in the fetoplacental circulation. VEGF-165 was found to be a potent vasodilator of the fetoplacental circulation (maximum response: 77% of previous steady-state fetal-side inflow hydrostatic pressure after preconstriction with U46619; EC50 = 71 pM). This vasodilatory effect was mediated by the VEGFR-2 receptor and nitric oxide in a manner-independent of the involvement of prostacyclin and the src-family tyrosine kinases. However, nitric oxide could explain only 50% of the vasodilatory effect. Finally, we measured the permeability of the perfused placenta to inert hydrophilic tracers and found no difference in the presence and absence of VEGF.
引用
收藏
页码:4734 / 4744
页数:11
相关论文
共 50 条
  • [1] Vascular endothelial growth factor-165 (VEGF165) is a vasodilator of the human fetal placental vasculature
    Brownbill, P
    Brockelsby, JC
    Sibley, CP
    PLACENTA, 2004, 25 (8-9) : A18 - A18
  • [2] THE TRANSFER OF ZINC ACROSS THE TERM DUALLY PERFUSED HUMAN PLACENTAL LOBULE
    PAGE, KR
    ABRAMOVICH, DR
    AGGETT, PJ
    TODD, A
    DACKE, CG
    QUARTERLY JOURNAL OF EXPERIMENTAL PHYSIOLOGY AND COGNATE MEDICAL SCIENCES, 1988, 73 (04): : 585 - 593
  • [3] Vasorelaxation Effect and Mechanism of Action of Vascular Endothelial Growth Factor-165 in Isolated Perfused Human Skin Flaps
    Huang, Ning
    Ashrafpour, Homa
    Levine, Ronald H.
    Forrest, Christopher R.
    Neligan, Peter C.
    Lipa, Joan E.
    Pang, Cho Y.
    JOURNAL OF SURGICAL RESEARCH, 2012, 172 (01) : 177 - 186
  • [4] Vasoactivity to and Endogenous Release of Vascular Endothelial Growth Factor in the in vitro Perfused Human Placental Lobule from Pregnancies Complicated by Preeclampsia
    Brownbill, P.
    Mills, T. A.
    Soydemir, D. F.
    Sibley, C. P.
    PLACENTA, 2008, 29 (11) : 950 - 955
  • [5] The vasodilatory response to vascular endothelial growth factor (VEGF) in the fetoplacental vasculature of the in vitro dually perfused placental lobule is potentiated in intrauterine growth restriction (IUGR) and preeclampsia (PE).
    Brownbill, P
    Sibley, CP
    JOURNAL OF THE SOCIETY FOR GYNECOLOGIC INVESTIGATION, 2006, 13 (02) : 228A - 228A
  • [6] Human skeletal myoblasts transfection with human vascular endothelial growth factor-165 using cationic liposome
    Esa, W.
    Deng, Wei
    Haider, K. H.
    Ye, Lei
    Mahendran, R.
    Law, P. K.
    Ge, R.
    Lim, Y. T.
    Teh, M.
    Sim, E. K. W.
    HYPERTENSION, 2006, 48 (04) : 773 - 773
  • [7] Construction and expression of a bicistronic vector containing human bone morphogenetic protein 2 and vascular endothelial growth factor-165 genes in vitro
    TIAN XiaobinSUN LiZHANG YukunGAO YongFU Dehao and YANG Shuhua Department of OrthopedicsPeoples Hospital of GuizhouProvinceGuiyangGuizhou ChinaDepartment of OrthopedicsUnion HospitalTongji MedicalCollege of Huazhong Science and Technology UniversityWuhanHubei China
    中华医学杂志(英文版), 2009, (04) : 471 - 473
  • [8] Construction and expression of a bicistronic vector containing human bone morphogenetic protein 2 and vascular endothelial growth factor-165 genes in vitro
    Tian Xiao-bin
    Sun Li
    Zhang Yu-kun
    Gao Yong
    Fu De-hao
    Yang Shu-hua
    CHINESE MEDICAL JOURNAL, 2009, 122 (04) : 471 - 473
  • [9] Imaging gastrointestinal tumours using vascular endothelial growth factor-165 (VEGF165) receptor scintigraphy
    Li, S
    Peck-Radosavljevic, M
    Kienast, O
    Preitfellner, J
    Hamilton, G
    Kurtaran, A
    Pirich, C
    Angelberger, P
    Dudczak, R
    ANNALS OF ONCOLOGY, 2003, 14 (08) : 1274 - 1277
  • [10] Modified LDL decreases the 123I-vascular endothelial growth factor-165 binding to human endothelial cells.
    Li, SR
    Yang, Q
    Koller, E
    Novotny, C
    Angelberger, P
    Weich, HA
    Valent, P
    Kapiotis, S
    Speiser, W
    Virgolini, I
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1999, 26 (09): : 1078 - 1078